Acute coronary syndromes with high thrombotic burden: therapeutic innovations

Antiplatelet agents represent one of the cornerstones of drug therapy for acute coronary syndromes (ACS). In the last decade, the arrival of prasugrel and ticagrelor, faster and more powerful oral platelet receptor P2Y12 inhibitors compared to clopidogrel, significantly improved platelet inhibition...

Descripción completa

Detalles Bibliográficos
Autores principales: Menozzi, Alberto, Caretta, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904081/
https://www.ncbi.nlm.nih.gov/pubmed/33654473
http://dx.doi.org/10.1093/eurheartj/suaa144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904081/
https://www.ncbi.nlm.nih.gov/pubmed/33654473
http://dx.doi.org/10.1093/eurheartj/suaa144

Ejemplares similares